

2021/22 Performance Dashboard

This dashboard (comprising of the tabs within) provides an overview of research activity across NHS Wales.
Each tab shows organisational progress against Welsh Government's Key Indicators for Performance.

In light of the unprecedented situation presented through COVID-19, Welsh Government fully understands that there will be considerable impact on R&D performance and key indicators as outlined in the 'Delivery Framework' due to the suspension and pausing of non-commercial and commercial portfolio research planned to take place during 2021/22. Throughout this next year, research activity will continue to be monitored, and Welsh Government's R&D Division will take account of the current disruption to the research environment and take a pragmatic view on the information feeding into NHS R&D performance indicators.

Summary

This tab summarises the current performance of all key indicators.

This information can be filtered by NHS organisation (using the filter dropdown in the top right).

Each indicator tile is linked to the appropriate tab within this dashboard - to follow each link please click on the tile.

Includes activity from portfolio non-commercial studies and all commercial studies.

06/09/21

Data cut date

93%

Site Level Data Completeness

Select NHS Organisation

Swansea Bay University HB

C1/C2:

Median no. of days to first recruited participant

138.00

Non-Commercial

154.0

Commercial

C3/C4 Open:

% of Open Studies Recruiting to Time & Target

64%

Open Non-Commercial

24%

Open Commercial

C3/C4 Closed:

% of Closed Studies Recruiting to Target

58%

Closed Non-Commercial

20%

Closed Commercial

E7/E8:

% of Non-Recruiting Studies

8%

Non-Commercial

60%

Commercial

Non-KI Metrics:

Number of Open and Recruiting Studies

47

Non-Commercial

9

Commercial

Number of Participants Recruited

475

Non-Commercial

74

Commercial



C1: Time taken from receipt of Local Information Pack to recruitment of 1st Participant into non-commercial HCRW Portfolio studies

Includes only sites where the planned target is more than one participant per month (unless this has been achieved within 70 days of site activation). Excludes studies where there is missing data on LIP or first participant date.

138.00

Median No. of Days to 1st Patient


Studies Recruiting First Participant

NHS Organisation	IRAS ID	Short Title	Date Site Selected	Date Site Confirmed	First Participant Recruited at Site	No. of Days to 1st Pt
SB UHB	177719	TRACC - Predicting Relapse in eArly Colorectal Cancer	Friday, March 13, 2020	Thursday, May 20, 2021	Wednesday, July 07, 2021	481
SB UHB	265870	Ustekinumab Real World Evidence Study	Wednesday, June 02, 2021	Monday, July 12, 2021	Friday, July 16, 2021	44
SB UHB	274639	Physician Associates in Wales	Monday, May 18, 2020	Thursday, May 27, 2021	Friday, July 02, 2021	410
SB UHB	284958	Giant PANDA	Wednesday, January 20, 2021	Wednesday, May 12, 2021	Monday, June 07, 2021	138
SB UHB	288506	UK-ROX	Friday, April 16, 2021	Tuesday, July 06, 2021	Monday, July 12, 2021	87
Total						138

Number of studies in 2021/22 recruiting first participant to date



Median Number of Days To Recruit first Participant





C2: Time taken from receipt of Local Information Pack to recruitment of 1st Participant into Commercial studies



Includes only sites where the planned target is more than one participant per month (unless this has been achieved within 70 days of site activation). Please note, the median number of days may be highly variable if only a small number of studies have recruited their first participant in 2021/22


Studies Recruiting First Participant

NHS Organisation	IRAS ID	Short Title	Date Site Selected	Date Site Confirmed	First Participant Recruited at Site	No. of Days to 1st Pt
SB UHB	290564	PROPHETIC	Wednesday, March 10, 2021	Monday, June 07, 2021	Wednesday, July 21, 2021	133
SB UHB	292980	LI8998 Abemaciclib MBC Chart Review Study	Thursday, January 28, 2021	Wednesday, July 07, 2021	Thursday, July 22, 2021	175
Total						154


154

Median No. of Days to 1st Patient

Number of studies in 2021/22 recruiting first participant to date



Median Number of Days To Recruit first Participant






C3 Open: % of Open non-commercial HCRW Portfolio Studies Recruiting to Time & Target




Studies RAG rated black are excluded from measure against this KI. This may be due to the study being Primary Care or missing data sets that are required for calculation.

% of Open Studies RAG Rated Green by NHS Organisation




RAG Rating	R		A		G		Total	
NHS Organisation	No. of Open Studies	% RAG	No. of Open Studies	% RAG	No. of Open Studies	% RAG	No. of Open Studies	% RAG
SB UHB	18	25%	8	11%	47	64%	73	100%
Total	18	25%	8	11%	47	64%	73	100%

% of Open Studies RAG Rated Green



Open Studies RAG Rating % by NHS Organisation

RAG Rating ● R ● A ● G ● B






C4 Open: % of Open Commercial Studies Recruiting to Time & Target




Studies RAG rated black are excluded from measure against this KI. This may be due to due the study being Primary Care or missing data sets that are required for calculation.

% of Open Studies RAG Rated Green by NHS Organisation




RAG Rating	R		A		G		Total	
NHS Organisation	No. of Open Studies	% RAG	No. of Open Studies	% RAG	No. of Open Studies	% RAG	No. of Open Studies	% RAG
SB UHB	14	67%	2	10%	5	24%	21	100%
Total	14	67%	2	10%	5	24%	21	100%

% of Open Studies RAG Rated Green



Open Studies RAG Rating % by NHS Organisation

RAG Rating ● R ● A ● G ● B






C3 Closed: % of Closed non-commercial HCRW Portfolio Studies Recruiting to Target


Studies RAG rated black are excluded from measure against this KI. This may be due to due the study being Primary Care or missing data sets that are required for calculation.



% Closed Studies RAG Rated Green by NHS Organisation




% RAG Rated Green



Closed Studies RAG Rating % by NHS Organisation

RAG Rating R G B



RAG Rating	R		G		Total	
NHS Organisation	No. of Closed Studies	% RAG	No. of Closed Studies	% RAG	No. of Closed Studies	% RAG
SB UHB	5	42%	7	58%	12	100%
Total	5	42%	7	58%	12	100%

Closed Studies with RAG and Closure Reason

SiteShortName	Short Title	RAG	Closure Reason
SB UHB	DIPLOMA trial version 1.0	R	
SB UHB	ENRICH Ibrutinib for untreated mantle cell lymphoma	G	Recruitment Finished
SB UHB	JaW PrinT	R	
SB UHB	POSNO	G	
SB UHB	R4VaD	G	
SB UHB	RETAKE - Return to Work After Stroke	G	
SB UHB	Spironolactone for Adult Female Acne	G	
SB UHB	The CIPHER study	G	
SB UHB	TRIDENT	R	
SB UHB	Ustekinumab in adolescents with recent-onset type	R	
Total			




C4 Closed: % of Closed Commercial Studies Recruiting to Target



Studies RAG rated black are excluded from measure against this KI. This may be due to due the study being Primary Care or missing data sets that are required for calculation.

% Closed Studies RAG Rated Green by NHS Organisation




RAG_Sorted NHS Organisation	R No. of Closed Studies	% RAG	G No. of Closed Studies	% RAG	Total No. of Closed Studies	% RAG
SB UHB	4	80%	1	20%	5	100%
Total	4	80%	1	20%	5	100%

% RAG Rated Green



Closed Studies RAG Rating % by NHS Organisation

RAG Rating ● R ● G ● B



Closed Studies with RAG and Closure Reason

SiteShortName	Short Title	RAG	Closure Reason
SB UHB	1245.110 EMPEROR-Preserved Study	R	Recruitment Finished
SB UHB	Coronavirus-Like Particle COVID-19 Vaccine (CP-PRO-CoVLP-021)	B	
SB UHB	NN1436-4477	B	Recruitment Finished
SB UHB	Pembrolizumab + Olaparib 1L treatment of Metastatic Nonsquamous NSCLC	R	
SB UHB	Portico NG Approval Study	G	Recruitment Finished
SB UHB	PROTECT 021IGAN17001	R	Recruitment Finished
SB UHB	VOLUME	R	
Total			



C5: % of Non-Recruiting non-commercial HCRW Portfolio Studies




Studies that have closed with zero recruitment. Click on the bars on the graph below to show relevant studies on the bottom right table.

% of HCRW Portfolio Non-Recruiting Studies

HCRW Portfolio Studies Recruiting/Non-Recruiting

Site Recruited Status ● NR ● R



NHS Organisation

	NR	R	Total
SB UHB	1	11	12
Total	1	11	12

Closed Studies and status

Site	IRAS ID	Short Title	Site Recruited Status
SB UHB	232201	DIPLOMA trial version 1.0	NR
SB UHB	180518	ENRICH Ibrutinib for untreated mantle cell lymphoma	R
SB UHB	241919	JaW PrinT	R
SB UHB	137785	POSNOG	R
SB UHB	239109	R4VaD	R
SB UHB	234874	RETAKE - Return to Work After Stroke	R
SB UHB	246637	Spironolactone for Adult Female Acne	R



C6: % of Non-Recruiting Commercial Studies




Studies that have closed with zero recruitment. Click on the bars on the graph below to show relevant studies on the bottom right table.


% of Commercial Non-Recruiting Studies

Commercial Studies Recruiting/Non-Recruiting

Site Recruited Status ● NR ● R



Closed Studies and status





Number of Open and Recruiting non-commercial HCRW Portfolio Studies




Includes only sites where participants have been recruited this year.

47


Total Open and Recruiting

Studies By Complexity



Studies per NHS Organisation

● No. of Studies | Last Year Comparison



NHS Organisation	CPMS Study ID	IRAS ID	Short Title	Site Study Status	Managing Specialty	2021-22 Recruits
SB UHB	1358	20971	EMBRACE	Open To Recruitment	Genetics	1
SB UHB	1409	31586	STAMPEDE	Open To Recruitment	Cancer	10
SB UHB	5655	185221	NCISH	Open To Recruitment	Mental health	10
SB UHB	7471	23389	UKALL 14	Open To Recruitment	Cancer	1
SB UHB	14152	126600	Clinical Characterisation Protocol for Severe Emerging Infection	Open To Recruitment	Infection	16
SB UHB	14362	108857	The Cleft Collective Cohort Studies	Open To Recruitment	Reproductive health and childbirth	3
SB UHB	16069	137785	POSNO	Closed to Recruitment, In Follow Up	Cancer	2
SB UHB	18067	120104	Add-Aspirin	Open To Recruitment	Cancer	2
SB UHB	18218	154468	AML19	Open To Recruitment	Cancer	1
Total						475

Number of Open and Recruiting Commercial Studies

Includes only sites where participants have been recruited this year.

9

Total Open and Recruiting

Studies By Complexity


Interventional

Observational

[NOT SET]

Studies per NHS Organisation

● No. of Studies | Last Year Comparison



NHS Organisation	CPMS Study ID	IRAS ID	Short Title	Site Study Status	Managing Specialty
SB UHB		269254	Portico NG Approval Study	Closed to Recruitment, In Follow Up	[NOT SET]
SB UHB		272652	ERME Study	Open To Recruitment	[NOT SET]
SB UHB	32891	227566	CA209-914 Nivolumab in Patients with Renal Cell Carcinoma	Open To Recruitment	Cancer
SB UHB	35000	243165	AEGIS-II / ApoA-I Event reducInG in Ischemic Syndromes II	Open To Recruitment	Cardiovascular Disease
SB UHB	45637	276439	Tirzepatide vs Dulaglutide on CV events in high risk T2DM patients	Open To Recruitment	Diabetes
SB UHB	45853	284188	The DAPA-MI Study	Open - No Recruitment Activity	Cardiovascular Disease
SB UHB	47217	295102	ONWARDS 6	Open To Recruitment	Diabetes
SB UHB	47416	290965	Phase III trial of inhaled anti-viral (SNG001) for SARS-	Open To Recruitment	Infection
Total					



Number of Participants Recruited into non-commercial HCRW Portfolio Studies



Includes only sites where participants have been recruited this year.

Confirmed / Provisional Recruitment

Confirmed

Provisional

475

Total Non-Commercial Recruitment


Studies By Complexity

Observational

Large Sample

Interventional

Recruitment per NHS Organisation



NHS Organisation	CPMS Study ID	IRAS ID	Short Title	Site Study Status	Managing Specialty	2021-22 Recruits
SB UHB	1358	20971	EMBRACE	Open To Recruitment	Genetics	1
SB UHB	1409	31586	STAMPEDE	Open To Recruitment	Cancer	10
SB UHB	5655	185221	NCISH	Open To Recruitment	Mental health	10
SB UHB	7471	23389	UKALL 14	Open To Recruitment	Cancer	1
SB UHB	14152	126600	Clinical Characterisation Protocol for Severe Emerging Infection	Open To Recruitment	Infection	16
SB UHB	14362	108857	The Cleft Collective Cohort Studies	Open To Recruitment	Reproductive health and childbirth	3
SB UHB	16069	137785	POSNOG	Closed to Recruitment, In Follow Up	Cancer	2
SB UHB	18067	120104	Add-Aspirin	Open To Recruitment	Cancer	2
SB UHB	18218	154468	AML19	Open To Recruitment	Cancer	1
SB UHB	18621	161147	CompARE Trial	Open To Recruitment	Cancer	1
SB UHB	20443	177719	TRACC - Predicting Relapse in eArly Colorectal Cancer	Open To Recruitment	Cancer	1
SB UHB	20664	173561	IBD Bioresource	Open To Recruitment	Gastroenterology	20
SR IHR	30433	178681	PARTNER	Open To Recruitment	Cancer	1
Total						475



Number of Participants Recruited into Commercial Studies



Includes only sites where participants have been recruited this year.

Confirmed / Provisional Recruitment

(Blank)

Confirmed

Provisional

74

Total Commercial Recruitment

Studies By Complexity

Observational

Interventional

Recruitment per NHS Organisation




NHS Organisation	CPMS Study ID	IRAS ID	Short Title	Site Study Status	Managing Specialty	2021-22 Recruits
SB UHB		269254	Portico NG Approval Study	Closed to Recruitment, In Follow Up	[NOT SET]	0
SB UHB		272652	ERME Study	Open To Recruitment	[NOT SET]	0
SB UHB	32891	227566	CA209-914 Nivolumab in Patients with Renal Cell Carcinoma	Open To Recruitment	Cancer	4
SB UHB	35000	243165	AEGIS-II / ApoA-I Event reducINg in Ischemic Syndromes II	Open To Recruitment	Cardiovascular Disease	1
SB UHB	45637	276439	Tirzepatide vs Dulaglutide on CV events in high risk T2DM patients	Open To Recruitment	Diabetes	1
SB UHB	45853	284188	The DAPA-MI Study	Open - No Recruitment Activity	Cardiovascular Disease	1
SB UHB	47217	295102	ONWARDS 6	Open To Recruitment	Diabetes	4
SB UHB	47416	290965	Phase III trial of inhaled anti-viral (SNG001) for SARS-CoV-2	Open To Recruitment	Infection	2
Total						74



Data Quality & Completeness Summary

Total completion percentage of site level fields on LPMS, per NHS organisation. Excludes primary care studies. For a breakdown by field type and details of missing data please see the [full data quality report](#).

% Site Level Data Completeness



All Wales Completion Percentage

